Core Viewpoint - ResMed (RMD) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors often rely on earnings estimates to determine a company's fair value, leading to significant stock transactions that affect price movements [4]. ResMed's Earnings Outlook - For the fiscal year ending June 2025, ResMed is expected to earn $9.02 per share, reflecting a 16.8% increase from the previous year [8]. - Over the past three months, the Zacks Consensus Estimate for ResMed has increased by 3.6%, indicating a positive trend in earnings estimates [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7]. - ResMed's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

ResMed (RMD) , a leading provider of cloud-connected medical devices, has unveiled new patient-centric products designed to enhance the therapy journey for sleep apnea patients. These include the addition of new features in myAir consumer patient engagement app, a Generative AI-enabled sleep health assistant, and travel gear to support CPAP (continuous positive airway pressure) treatment while traveling. The latest innovations capitalize on the rising popularity of digital wearables, like smartwatches and h ...

2030 ambition to help more than 500 million people worldwide achieve their full health potential Showcases integration of intelligent products and solutions within the ResMed ecosystem, designed to deliver a better experience, lower costs, and enhanced outcomes for patients and providers Introduces updated five-year financial outlook NEW YORK and SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today unveiled its 2030 Strategy to drive growth, profitability, and shareholder returns ...

ResMed makes it easier for people to manage their sleep health and stay on (continuous positive airway pressure) CPAP treatment by integrating its leading myAir™ consumer app with Apple and Android smartwatches. Introduces a Generative AI-enabled sleep health assistant to guide people on their journey to better sleep and new travel gear to help people stay on CPAP treatment while traveling. SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), the world's leading health technology comp ...

SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), the world's leading health technology company focused on sleep, breathing, and care delivered in the home, today announced a ResMed first in CPAP (continuous positive airway pressure) mask innovation with the launch of the AirTouch™ N30i. Designed to create a natural and comfortable sleep experience for users, the AirTouch N30i is a fabric-wrapped frame featuring a soft, breathable, and moisture-wicking design for optimal comfort in ...

SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), the world's leading health technology company focused on sleep, breathing, and care delivered in the home, today announced a ResMed first in CPAP (continuous positive airway pressure) mask innovation with the launch of the AirTouch™ N30i. Designed to create a natural and comfortable sleep experience for users, the AirTouch N30i is a fabric-wrapped frame featuring a soft, breathable, and moisture-wicking design for optimal comfort in ...

Core Insights - ResMed has launched new patient-centric products aimed at enhancing the therapy journey for sleep apnea patients, integrating digital wearables and generative AI for a personalized sleep health experience [2][4] Group 1: Product Innovations - The myAir™ app has been integrated with Apple and Android smartwatches, allowing users to monitor their CPAP therapy data easily [1][6] - A new generative AI-enabled sleep health assistant named Dawn provides 24/7 access to personalized guidance and information about sleep health and CPAP therapy [7] - The LUXE range of travel gear has been introduced, designed for CPAP users to facilitate therapy while traveling, featuring stylish and practical tote bags and backpacks [8] Group 2: Market Insights - ResMed's 2024 Global Sleep Survey revealed that 44% of Americans experience fewer than three good nights of sleep each week, highlighting a significant impact on quality of life [3] - The survey also indicated that 54% of respondents are interested in purchasing wearable devices with sleep-tracking capabilities, reflecting a growing focus on sleep health [3] Group 3: Patient Engagement - The myAir app has shown to significantly increase CPAP usage, with 87% of patients achieving therapy compliance through interactive coaching and nightly sleep data tracking [5] - New features in the myAir app include sleep staging integration, personalized coaching based on behavior science, and a holistic view of health metrics, all aimed at improving user engagement with CPAP therapy [6]

Core Insights - ResMed Inc (NYSE: RMD) has achieved double-digit revenue and profit growth over the past 9 years, contrasting with the single-digit revenue growth typical in its sector, primarily due to continuous acquisitions [1] Company Performance - The company has consistently outperformed its industry peers by leveraging strategic acquisitions to drive growth [1] Industry Context - The sector in which ResMed operates is characterized by single-digit revenue growth, highlighting the company's exceptional performance relative to its industry [1]

Key Takeaways The S&P 500 ended 0.3% lower on Wednesday, Sept. 18, as the Federal Reserve announced its first interest-rate cut since March 2020. ResMed shares tumbled after analysts said the likely label expansion of popular weight-loss drugs to treat sleep apnea could hurt demand for the company's devices. General Motors stock increased as the carmaker introduced adapters allowing drivers to power up GM EVs using Tesla's charging station network. Major U.S. equities indexes ended lower on Wednesday after ...

A looming threat from a very powerful rival could significantly dampen a key business for the company. Healthcare technology company ResMed's (RMD -5.12%) stock wasn't quite the picture of health on Wednesday. The shares lost more than 5% of their value on news of an analyst's downgrade and his new, bearish outlook. That performance didn't look good against that of the S&P 500 index, which fell a comparatively light 0.3%. A change in recommendation for the worse Well before market open that day, Wolfe Resea ...